Reviewing MediWound Ltd. (MDWD)’s and Asterias Biotherapeutics Inc. (:)’s results

As Biotechnology businesses, MediWound Ltd. (NASDAQ:MDWD) and Asterias Biotherapeutics Inc. (:), are affected by compare. This especially applies to their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
MediWound Ltd. 3 0.15 16.99M 0.43 6.71
Asterias Biotherapeutics Inc. N/A 0.00 N/A -0.37 0.00

Table 1 demonstrates MediWound Ltd. and Asterias Biotherapeutics Inc.’s top-line revenue, earnings per share and valuation.


Table 2 represents MediWound Ltd. (NASDAQ:MDWD) and Asterias Biotherapeutics Inc. (:)’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
MediWound Ltd. 565,899,477.07% 33.9% 10.4%
Asterias Biotherapeutics Inc. 0.00% 0% 0%

Analyst Recommendations

The following table shown below contains the ratings and recommendations for MediWound Ltd. and Asterias Biotherapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
MediWound Ltd. 0 0 1 3.00
Asterias Biotherapeutics Inc. 0 0 0 0.00

MediWound Ltd.’s upside potential currently stands at 81.52% and an $5.5 average price target.

Institutional and Insider Ownership

Institutional investors held 33% of MediWound Ltd. shares and 13.75% of Asterias Biotherapeutics Inc. shares. Insiders held 41.5% of MediWound Ltd. shares. Comparatively, insiders own roughly 40.53% of Asterias Biotherapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
MediWound Ltd. -4.35% -0.69% -10.9% -31.58% -46.84% -29.56%
Asterias Biotherapeutics Inc. 0% 0% 0% 0% 0% 0%


MediWound Ltd. beats on 10 of the 11 factors Asterias Biotherapeutics Inc.

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products in Israel. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine. The company develops therapeutic products in the areas of neurology and oncology. Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. The company also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.